Pharmacokinetics of roflumilast and roflumilast-N-oxide after single and repeated oral administration of 250 μg or 500 μg roflumilast - an open, randomized, two-period crossover study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, randomized, two-period crossover study in healthy subjects.